Alexandria Real Estate Equities, Inc (ARE) Stock News

Klépierre, Europe's leading shopping mall operator, has raised its full-year 2026 guidance with EBITDA expected to reach a minimum of €1,150 million. The company demonstrated strong execution in a dynamic retail market, driving organic growth. As of July 31, 2026, the company had 286.86 million shares outstanding.

Kirby McInerney LLP is investigating Jefferies Financial Group for potential securities law violations related to alleged misleading disclosures about the company's exposure to First Brands Group, a bankrupt auto-parts supplier, through its asset-management unit Point Bonita Capital. The SEC is reportedly investigating claims that Jefferies misled investors, with Point Bonita funds owed approximately $715 million from companies that purchased First Brands' parts. Jefferies disclosed a $30 million loss tied to First Brands' collapse, and the stock declined 9% on the news.

Law firm Levi & Korsinsky has filed a class action lawsuit against ARS Pharmaceuticals for allegedly making false and misleading statements regarding expanded insurance coverage for its drug neffy through CVS Caremark. The company failed to meet its July 1, 2026 deadline for coverage expansion, causing the stock to plummet 23.9% on June 25, 2026. Investors who purchased securities between March 9 and June 24, 2026 can join the lawsuit with a lead plaintiff deadline of October 5, 2026.

Class action law firm Monteverde & Associates PC is investigating four merger and acquisition transactions: Planet 13 Holdings' merger with Vireo Growth, Olin Corporation's merger with Huntsman Corporation, and First Seacoast Bancorp's sale to Cambridge Financial Group. The firm is encouraging shareholders to contact them regarding potential concerns with these deals.

Bernstein Liebhard LLP, an investor rights law firm, has announced investigations into potential breaches of fiduciary duty by directors and officers at AeroVironment, Capricor Therapeutics, and Calix. The firm is seeking to determine whether company leadership fulfilled obligations to shareholders and whether legal remedies may be available. Current shareholders are encouraged to contact the firm for consultation.

Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of Gartner, Inc. The law firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. The investigation targets shareholders who purchased shares before February 24, 2025.

Bernstein Liebhard LLP has launched investigations into potential breaches of fiduciary duty by directors and officers at CarMax, Inc., Capricor Therapeutics, Inc., and Calix, Inc. The firm is seeking to determine whether company leadership acted in shareholders' best interests and is encouraging affected shareholders to contact them for legal consultation.

Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of Calix, Inc. The law firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. The investigation focuses on shareholders who purchased shares before January 28, 2026.

VINCI, a French public limited company, disclosed its capital structure as of 31 July 2026, with 587,033,654 total shares and €1,467,584,135.00 in share capital. The company announced the implementation of its share buyback programme through a share purchase agreement signed with an investment partner.

Law firm Julie & Holleman is investigating Personalis' proposed acquisition by Tempus AI for $16.25 per share, raising concerns about fair value and potential conflicts of interest given Tempus' existing significant equity stake and strategic partnership with Personalis since 2023.

Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether the boards of MarketAxess Holdings, CBIZ, Sanara MedTech, and TriCo Bancshares breached fiduciary duties by failing to conduct fair processes and potentially underpaying shareholders. The firm is seeking shareholders to discuss potential class action lawsuits.

A securities fraud lawsuit has been filed against GPGI, Inc. alleging the company misled investors about its acquisition of Husky Technologies Limited, overstating its value and earnings projections while downplaying management fees to Resolute Holdings. Following short seller allegations in February 2026 and disappointing Q4 2025 and Q1 2026 results, GPGI shares declined significantly, with the company cutting 2026 guidance substantially. Investors have until September 14, 2026 to request lead plaintiff appointment.

Kirby McInerney LLP has filed a securities fraud class action lawsuit against Insulet Corporation on behalf of investors who purchased securities between February 21, 2025 and May 26, 2026. The lawsuit alleges that Insulet failed to disclose defective manufacturing controls and safety risks. Two significant product corrections were announced in March and May 2026, resulting in substantial stock price declines of approximately 7% and 5% respectively. The deadline to request lead plaintiff appointment is August 31, 2026.

DSV A/S reported EBIT before special items of DKK 6,255 million for Q2 2026, demonstrating positive earnings growth despite volatile market conditions. The company will release its full H1 2026 interim results on July 22, 2026, with a webcast and conference call at 11:00 am CEST.

Julie & Holleman LLP is investigating Personalis Inc.'s proposed acquisition by Tempus AI for $16.25 per share. The law firm is concerned about potential conflicts of interest given Tempus' existing significant equity stake and strategic relationship with Personalis since 2023, and whether shareholders are receiving fair value for their shares.

Monteverde & Associates PC is investigating Cross Country Healthcare's proposed sale to KL Criss Cross Intermediate, LLC for $13.25 per share in cash. The firm is encouraging shareholders to act before the July 16, 2026 vote to determine if the deal is fair.

Law firm Levi & Korsinsky has filed a class action lawsuit against Planet Fitness for allegedly providing false and misleading statements about customer acquisition and marketing metrics. The company's updated marketing campaign failed to resonate with its core demographic, leading to slower-than-expected membership growth in Q1 2026. Planet Fitness subsequently slashed full-year growth guidance and withdrew its three-year growth targets. The stock declined 31.19% on May 7, 2026, following the disappointing earnings announcement.

Brancous LP1, a shareholder of Braemar Hotels & Resorts, criticizes the Board for wasting company resources attacking shareholders instead of negotiating a lower Ashford termination payment. The shareholder claims the Board is pursuing a 'stealth liquidation' through asset sales to trigger a $480 million Change of Control payment to Ashford, which Brancous estimates at $7.00 per share. Brancous demands the Board declare a special dividend of at least $1.00 per share, renegotiate the Ashford payment, and allow shareholders to elect an independent Board.

A securities class action lawsuit has been filed against Nano-X Imaging (NNOX) alleging the company made false statements about operational efficiency and product demand while concealing poor manufacturing alignment, increased cash burn, and restructuring risks. The lawsuit covers investors who purchased securities between March 31, 2025 and April 17, 2026. The deadline to seek lead plaintiff status is August 11, 2026. The action was triggered after Nano-X reported a $33.4 million net loss in Q4 2025, including a $17.5 million impairment charge related to restructuring at its Korean facility, causing the stock to fall 24.39%.

A federal securities class action has been filed against Grail, Inc. (NASDAQ: GRAL) alleging that company executives made false and misleading statements about the NHS-Galleri cancer detection trial's likelihood of success while concealing material adverse facts. On February 19, 2026, Grail announced the trial failed to achieve its primary endpoint, causing the stock to plummet 50.55% in a single day from $101.53 to $50.21 per share. Investors who purchased GRAL stock between May 13, 2025 and February 19, 2026 may be eligible to participate in the class action, with a deadline of August 4, 2026 to seek lead plaintiff appointment.

Faruqi & Faruqi, LLP is investigating securities fraud claims against Erasca, Inc. (NASDAQ: ERAS) for allegedly making false statements about its ERAS-0015 drug candidate based on improper comparisons to Revolution Medicines' compound. The company disclosed patent infringement allegations and a patient death in Phase 1 trials on April 27, 2026, causing the stock to plummet from $21.49 to $9.90 per share over two trading days. Investors who purchased ERAS securities between January 14, 2025 and April 26, 2026 can seek lead plaintiff status by August 10, 2026.

A securities class action lawsuit has been filed against Peabody Energy Corporation for allegedly making false and misleading statements about its Centurion mine operations. The company provided overly positive guidance while concealing material operational challenges. Stock price declined significantly following corrective disclosures on March 30, 2026 (down 9.7%) and May 5, 2026 (down 5.7%) when the company revealed commissioning delays and reduced output expectations. The deadline to seek lead plaintiff status is August 24, 2026.

A federal securities class action has been filed against Lucid Group alleging that the company and its executives made false and misleading statements by concealing a supplier quality issue that significantly disrupted Lucid Gravity deliveries and overstating manufacturing capabilities. The lawsuit covers investors who purchased LCID stock between February 25, 2026 and April 13, 2026. The deadline to seek lead plaintiff appointment is July 28, 2026.

A securities class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) alleging that the company made false and misleading statements about its financial guidance. Embecta's stock plummeted 57.8% on May 5, 2026, after the company disclosed a revenue decline of over 14% and cut its fiscal year 2026 guidance, primarily due to weakness in pen needle sales. The deadline to seek lead plaintiff status is August 17, 2026.

Faruqi & Faruqi, LLP is investigating a federal securities class action against GeneDx Holdings Corp. (NASDAQ: WGS) for allegedly making false and misleading statements about its Fabric Genomics acquisition and overstating the durability of reimbursement rates. On May 4, 2026, GeneDx disclosed missed Q1 results, cut 2026 guidance from $540-555M to $475-490M, and took a $31.3M goodwill impairment charge on the $36.5M Fabric Genomics acquisition. The stock fell 49% ($33.42 per share) on the news. The deadline to seek lead plaintiff appointment is August 3, 2026.

Law firm Levi & Korsinsky has filed a class action lawsuit against Photronics, Inc. alleging the company made materially false statements about its product pipeline and demand while concealing critical bottlenecks. Following the company's May 28, 2026 earnings announcement revealing a 11% sequential IC revenue decline and missed guidance, Photronics' stock plummeted 36.42% in a single day. The lead plaintiff deadline is set for September 4, 2026.

Singapore-based COMPUTESHARE PTE. LTD. announced the launch of its global membership ecosystem with a closed beta in China scheduled for July 16, 2026. The company operates two core divisions: Enterprise AI Customization Services and a Global Membership Ecosystem. It leverages its T3+T4 computing infrastructure to offer AI services including customer service, content production, and digital humans to enterprises and e-commerce providers.

Hub Group, Inc. faces a securities fraud lawsuit after restating financial statements due to approximately $77 million in understatements of purchased transportation costs and accounts payable. The company's stock fell 18% in February 2026 and an additional 13% in May 2026 following disclosure of material misstatements in its 2023, 2024, and 2025 financial reports. Investors who purchased shares between April 28, 2023, and May 11, 2026, may be eligible to recover losses.

A securities fraud class action lawsuit has been filed against ADMA Biologics for allegedly engaging in channel stuffing, undisclosed related party transactions, and lacking adequate internal controls. Following a March 2026 short seller report by Culper Research alleging revenue manipulation through excess product stocking with extended payment terms, ADMA shares declined approximately 46% over three trading days. The lawsuit covers investors who purchased securities between August 9, 2024 and March 25, 2026.

Kirby McInerney LLP has filed a securities fraud class action lawsuit against Nano-X Imaging Ltd. on behalf of investors who purchased securities between March 31, 2025 and April 17, 2026. The lawsuit alleges that Nano-X overstated operational efficiency gains and product demand while concealing poor alignment between production and actual demand, leading to increased operating expenses and cash burn. On April 20, 2026, Nano-X disclosed a $17.5 million impairment charge related to restructuring its Korean manufacturing facility and announced its CFO's departure, causing the stock to decline 25% from $2.85 to $2.15 per share.